HOLON, Israel, May 22, 2019 /PRNewswire/ -- Compugen
Ltd. (NASDAQ: CGEN), a leader in predictive discovery and
development of first-in-class therapeutics for cancer
immunotherapy, today announced that Anat
Cohen-Dayag, PhD, President and CEO, will present a
corporate overview and update at the Jefferies 2019 Healthcare
Conference in New York, on
Tuesday, June 4, 2019, at
4:30 PM ET.
To access live webcast of the presentation, please visit
Compugen's website. An archived version of the presentation will be
available after the presentation ends at the same location.
About Compugen
Compugen is a clinical-stage, therapeutic discovery and
development company utilizing its broadly applicable computational
discovery platforms to identify novel drug targets and develop
first-in-class therapeutics in the field of cancer immunotherapy.
The Company's therapeutic pipeline consists of immuno-oncology
programs against novel drug targets it has discovered
computationally, including T cell immune checkpoints and other
early-stage immuno-oncology programs focused largely on myeloid
targets. Compugen's business model is to enter into collaborations
for its novel targets and related drug product candidates at
various stages of research and development. The Company is
headquartered in Israel with
facilities in South San Francisco,
CA. Compugen's ordinary shares are listed on Nasdaq and the
Tel Aviv Stock Exchange under the ticker symbol CGEN. For
additional information, please visit Compugen's corporate website
at www.cgen.com.
Company contact:
Elana
Holzman
Director, Investor Relations and Corporate Communications
Compugen Ltd.
Email: elanah@cgen.com
Tel: +972(3)765-8124
Investor Relations contact:
Burns McClellan, Inc.
Jill Steier
Email: jsteier@burnsmc.com
Tel: +1-212-213-0006
View original
content:http://www.prnewswire.com/news-releases/compugen-to-present-at-the-jefferies-2019-healthcare-conference-300854909.html
SOURCE Compugen Ltd.